Bristol Myers Squibb partners with Hengrui Pharma in $15.2 billion, 13-asset deal

Bristol Myers Squibb announced a partnership with China’s Hengrui Pharma that includes 13 assets.

The transaction is reported to be valued at up to $15.2 billion, highlighting the scale of collaboration between a major Western biotech and the country’s largest pharmaceutical company.

Hengrui, which boasts one of the industry’s biggest pipelines, continues to draw Western partners as it expands its global footprint.